Critical analysis of the combination of dipyridamole plus acetylsalicylic acid versus acetylsalicylic acid alone in the secondary prevention of stroke

International Journal of Clinical Practice, Supplement

Volumn , Issue 97, 1998, Pages 3-6

  Wahlgren, N G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; DIPYRIDAMOLE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SECONDARY PREVENTION; STATISTICAL ANALYSIS; STROKE;

EID: 33749278723     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Antiplatelet Trialist's collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
2. Guiraud-Chaumeil B, Rascol A, David J et al. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaqettaires. Rev Neurol (Paris) 1982; 138: 367-385.
3. Bousser MG, Eschwege E, Haguenau M et al. 'AICLA' controlled trial of ASA and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
4. American-Canadian Co-operative Study Group. Persantin aspirin trial in cerebral ischaemia. Part II: endpoint results. Stroke 1983; 14: 99-103.
5. ESPS-1 Group. European Stroke Prevention Study. Stroke 1990; 21: 1122-1130.
6. Berthrand-Hardy JM, Cunha L, Forbes C et al. European Stroke Prevention Study 2: Baseline data. J Neurol Sci 1995; 131 : S1-S58.
7. Müller TH, Su CAPF, Weisenberger H et al. Dipyridamole alone or combined with low dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-186.
8. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-1349.
9. Dutch TIA Trial Study Group. A comparison of two doses of ASA (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266.
10. The ESPS-2 Group. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1997; 151 : S1-S77.